Francis McCormack, MD
Pulmonary Disease · Cincinnati, OHNPI 1083671564
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,799 of the $19,099 with a category attached, or 98.4%. Sanofi accounts for 65.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $14,615 and has fallen 89.1% since, to $1,600 in 2025.
Across 7 payments — averaging $2728.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$13K
- Insmed, Inc.$5K
- Modernatx, Inc.$2K
- Intuitive Surgical$135
- United Therapeutics Corporation$92
Across 13 payments — averaging $82,297 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.1M
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Consulting fees$18,79998%
- Food & beverage$3002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 3 | $12,511 |
| Insmed, Inc. | 1 | $4,760 |
| Modernatx, Inc. | 1 | $1,600 |
| Intuitive Surgical | 1 | $135 |
| United Therapeutics Corporation | 1 | $92 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XENPOZYME$2,584
- Da Vinci Surgical System$135
How this compares
$19,099 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sirolimus | 31 | $15,646 |
| Pirfenidone | 14 | $10,439 |
| Mycophenolate Mofetil | 21 | $3,778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $316 |
| Prednisone | 27 | $147 |
| Omeprazole | 15 | $17 |
| Famotidine | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Cincinnati
- Robert BaughmanCincinnati$640K
- Bruce CorserCincinnati$502K
- Mohammad SheattCincinnati$389K
- Jean ElwingCincinnati$320K
- Bruce TrapnellCincinnati$92K
- Arun JoseCincinnati$56K
- Joseph KhabbazaAkron$655K
- Kristin HighlandCleveland$551K
- Jason StieneckerLima$397K
- Mohammad KhanAkron$388K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.